Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal dominant disease characterized by a typical regional distribution, featuring composed patterns of clinically affected and unaffected muscles. No treatment is available for this condition, in which the pathophysiological mechanism is still unknown. Autologous transfer of myoblasts from unaffected to affected territories could be considered as a potential strategy to delay or stop muscle degeneration. To evaluate the feasibility of this concept, we explored and compared the growth and differentiation characteristics of myoblasts prepared from phenotypically unaffected muscles of five FSHD patients and 10 control donors. According to a clinically approved procedure, 10 9 cells of a high degree of purity were obtained within 16-23 days. More than 80% of these cells were myoblasts, as demonstrated by labeling of the muscle markers CD56 and desmin. FSHD myoblasts presented a doubling time equivalent to that of control cells; they kept high proliferation ability and did not show early telomere shortening. In vitro, these cells were able to differentiate and to express muscle-specific antigens. In vivo, they participated to muscle structures when injected into immunodeficient mice. These data suggest that myoblasts expanded from unaffected FSHD muscles may be suitable tools in view of autologous cell transplantation clinical trials.
Introduction
With an incidence of 1/20 000 in Occidental countries, facioscapulohumeral muscular dystrophy (FSHD) is considered a rare disease, but is the third most common inherited myopathy. 1 It is characterized by typical regional distribution with progressive weakening of face and shoulder girdle muscles, further extending to abdominal and pelvic girdle, and to humeral and anterior foreleg muscles. The disease is transmitted as an autosomal dominant trait and is associated with a deletion of an integral number of copies of a 3.3 kb tandem repeated unit termed D4Z4 located at the 4q subtelomeric region. This deletion results in an EcoRI fragment shorter than 35 kb, providing the molecular marker for FSHD diagnosis. 2, 3 While, in general population, D4Z4 comprises 11-150 U, FSHD patients carry less than 11 repeats. The disease is usually much worse (earlier onset and greater clinical severity) when the short 4q D4Z4 array is in the smaller size range (1-4 repeats). 4, 5 In spite of the advances in molecular biology, its pathophysiological mechanism has not been elucidated yet, nor has its anatomical specificity. The difficulty to define this disease exactly is mainly due to its complexity, since a profound misregulation of gene expression rather than a single gene defect seems to be involved. 6, 7 For this reason, no classical gene therapy approach can be considered yet (ie gene transfer, gene repair, exon skipping), prompting for the identification of new therapeutic concepts. No animal model is available, and no treatment can currently be recommended. 8 Among potential therapeutic strategies for muscular dystrophies, the intramuscular injection of cultured myoblasts (myoblast transplantation, MT) has been considered for generalized myopathies -mainly Duchenne muscular dystrophy (DMD). 9, 10 Unlike FSHD, this disease is characterized by diffuse muscle involvement leading to a progressive degeneration of the whole body musculature. The pathophysiological mechanism of DMD involves deficits of the dystrophin gene, and exhaustion of the myogenic reservoir secondary to multiple cycles of degeneration-regeneration. As a consequence, the remaining cells cannot sustain the large-scale expansions required for perpetual muscle regeneration, or use in clinical practice. [11] [12] [13] For this reason, the DMD myoblasts have been prepared from healthy donors, and MT has been performed in a heterologous context. The MT concept has been validated in normal and dystrophic mouse models, where injection of healthy myoblasts increased muscle mass and function. 14, 15 Despite positive results in these small rodents, [16] [17] [18] [19] [20] clinical trials have presented limited success. [21] [22] [23] [24] [25] [26] [27] [28] [29] Improvements of injection and immunosuppression parameters have recently been achieved in primates 9, 10, 30 and translated to the human situation with encouraging, although localized success. 31 Nevertheless, one of the most important problems of heterologous MT remains the immune response raised by the recipient against donor cells.
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This issue is completely avoided in the context of autologous MT, which has been successfully developed as an experimental treatment for postischemic heart failure or dilated cardiomyopathy, showing its feasibility, safety and its great clinical interest. [32] [33] [34] [35] [36] In some myopathic condition such as FSHD, characterized by a relatively localized muscle involvement, and the absence of therapeutic options, autologous MT could be considered as an alternative strategy. In this case, unaffected muscles could be the source of myoblasts to be transferred into affected muscles in order to improve their regeneration ability.
The validation of this concept requires the completion of four stages: (i) production and in vitro characterization of FSHD myoblasts from unaffected muscles, and comparison with myoblasts from muscles of healthy donors. This comparison would allow establishing if FSHD myoblasts grown from unaffected muscle, but still carrying the FSHD molecular defect, would manifest or not its deleterious effect when submitted to a large-scale expansion or in vitro differentiation. (ii) Evaluation in vivo of FSHD myoblast regenerating ability, through implantation into the skeletal muscles of relevant animal models. Upon validation of these first two steps, clinical trials should be considered as (iii) set up of a phase I assay dedicated to the assessment of safety and feasibility, and (iiii) set up of a phase II clinical trial dedicated to the evaluation of efficacy. This study regards the first two steps. We evaluated in vitro proliferation and differentiation and in vivo regenerating ability of myoblasts obtained from phenotypically unaffected muscles of five FSHD patients and of 10 control donors prepared in a previous clinical trial using the same procedures. 34 We could not observe any difference between FSHD and control myoblasts.
Results

Patient selection
Five FSHD patients (FSHD 1-5) carrying, respectively, 10, 7, 9, 6 and 7 D4Z4 repeats were included after giving their informed consent. These patients presented with a familial form of the disease. According to Brooke-Vignos functional scale, 37 all patients were ranked 2 for arms, and 1 for legs. Facial and shoulder girdle muscles were affected while no clinical involvement of the legs was evident. Muscle MRI did not show any fibrotic or adipose infiltration in the muscular territory elected for muscle biopsy. The 10 control donors (C 1-10) had been recruited in the context of a previous clinical study dedicated to the autologous MT in postinfarction left ventricular dysfunction. 34 The mean ages of the FSHD patients and control donors were, respectively, 5375 and 61711 years. All FSHD patients and controls were males.
Muscle biopsy and transmission to the cell culture laboratory FSHD patients and control donors underwent a right or left vastus lateralis muscle biopsy, which mean weights were, respectively, 1.170.1 and 12.970.4 g. The larger 
Cell production
The schedules of cell expansions are presented in Table 1 . Except for the FSHD2 biopsy, the methodology allowed to extract 1.13 Â 10 6 and 9.7 Â 10 5 cells/g of muscle from FSHD patients and controls, respectively (Figure 1a) . The cells were then seeded at low density (2000-4000/cm 2 ). Following a lag time (4-6 days), cells grew as isolated colonies. This first passage (P) allowed a homogeneous spreading of the cells and was performed before colonies were reaching confluence. The highest growth rates were observed between P1 and P2, with doubling times of 31.6 and 29.6 h for FSHD and control cells, respectively. Thereafter, the doubling times increased in both conditions within the same proportions (Figure 2a and b) . From Day 0 (D0) to P3, the cells underwent 7.0 and 6.6 divisions, respectively. At P3, 156 Â 10 6 FSHD cells and 957 Â 10 6 control cells were obtained. Since doubling times were equivalent, the difference was attributed to the starting sizes of biopsies, the control being 12 times larger than the FSHD. The threshold number of cells required for potential clinical trials was arbitrarily established at 8 Â 10 8 on the basis of previous experience. 34 To reach this number, FSHD cells were grown up to P5, for three supplementary divisions, and overall performed 9.8 divisions. We produced 8.5 Â 10 8 to 1.6 Â 10 9 myoblasts (mean 1.06 Â 10 9 ) within 22.7 days. This result is to be compared to the production of 6.5 Â 10 8 to 1.2 Â 10 9 myoblasts (mean 9.5 Â 10 8 ) within 15.8 days in the historical control group. Our results thus suggest that the initial numbers of myogenic progenitors present per gram of disease or control muscles were equivalent. Myoblasts were small, fusiform or polygonal cells, mostly slightly refringent, and not evenly spread onto the substrate. The nuclear/cytoplasm ratio was generally high, and two or three dark nucleoli were clearly distinguishable. No morphological difference was observed between FSHD and control cultures at different passages (Figure 3a-d) .
Cell viability
As estimated by propidium iodide exclusion, the viability of the cells at each passage and at the time of final harvest was above 90% in both the FSHD and control groups (Figure 1b) .
Phenotypic characterization
Myoblasts express the surface NCAM antigen, previously described as leu-19, 5.1H11, NKH-1 or CD56. Muscle cells (cardiac, smooth and skeletal types) also express desmin, an intracellular cytoskeleton protein, at an early stage of differentiation. [38] [39] [40] [41] As presented in Figure 1c and d, the cell culture methodologies allowed the rapid and reproducible emergence of myoblasts as a dominant population. The percentage of CD56-and desmin-positive cells increased rapidly, reaching a plateau (above 80%) within two passages and remained elevated throughout the culture. Among the whole-cell population, the specific growth rate of myoblasts can be calculated from CD56 Production and characterization of FSHD myoblasts J-T Vilquin et al evaluation. The initial content in CD56-positive cells was not assessable in the case of FSHD patients because the initial number of cells was too low for precise cytofluorimetric evaluation. Nevertheless, our data indicate that myoblasts first grew rapidly (Figure 2c and d) and presented the shortest doubling times between P1 and P2. Subsequently, the doubling times were increased. Over the P1-P3 period, growth rates were comparable (doubling times of 31.2 versus 32.8 h respectively). In the control group, myoblasts underwent more divisions than the whole-cell populations during the first phases of the culture (D0-P1, 3.7 versus 1.6; and D0-P3, 8.8 versus 6.6). This may explain their aptitude to become and remain the dominant cell type in the primary cultures.
Proliferative ability
Following the final harvesting (P5 or P6), cells obtained from FSHD patients were further subcultured until the drop of CD56-positive cells under 50%. The final theoretical yield was obtained by multiplication of the expansion ratios observed at each passage. This calculation allowed extrapolating the proliferative potential of these cells (Table 2 ). These data indicate that the cells produced by serial expansions still kept the ability to grow for at least two (patient FSHD1) to seven (patients FSHD3 and FSHD4) additional passages.
In vitro differentiation
When placed into differentiation conditions, the cells fused to form multinucleated myotubes (Figure 3e -h). Their sizes and shapes could vary, both in patient and control cultures. Myotubes may contain two to dozens of nuclei. Some were branched, and others were straight. In some instances, large and flat syncitia were observed. No morphological difference was noted between FSHD and control myoblasts. The fast and slow isoforms of myosin heavy chain (MyHC) were expressed according to the same chronological pattern in FSHD and control myotubes. No expression was observed at D0. Fast MyHC isoform appeared in myotubes at D1, while slow isoform appeared at D3. Both persisted up to D6 (Figure 4 ). No significant difference was observed between fusion indexes calculated at different time points (D1, D3, D6) in FSHD and control cultures (data not shown).
Telomere size
The telomere sizes were evaluated for three out of five patients and two controls. They were estimated to be 7.970.1 (FSHD1), 6.870.3 (FSHD4) and 7.970.3 (FSHD5). As a mean (7.53), they did not differ from that of the two controls (6.970.2 and 7.470.3), and all telomere sizes kept within the range of normal values (6.5-8.5), as published.
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Number of D4Z4 repeats
The number of D4Z4 repeats was assessed by the same laboratory (Dr M Jeanpierre) first at the time of patient selection as a molecular confirmation of the clinical diagnosis, and then on cell cultures at the end of the production process (P5 or P6). No difference between these two values was noted (data not shown). These data exclude the possibility that myoblasts not harboring the FSHD mutation would have taken over mutated myoblasts, as could result from the expression of a somatic mosaicism. Production and characterization of FSHD myoblasts J-T Vilquin et al Figure 3 Morphological aspect of FSHD and control myoblasts during proliferation or in vitro differentiation. Inverted phase contrast microphotographs were performed before the onset of differentiation (a-d) and 6 days after (e-h). Myoblasts are small, polygonal or slightly fusiform cells with a high nucleocytoplasmic ratio. No morphological difference was observed between control (a) and FSHD myoblasts (b-d illustrate FSHD2, FSHD3 and FSHD5, respectively). Myotubes presented various shapes: some were branched (e, f), flattened (g) or straight (e, h). They contained two to dozens of nuclei presenting one or two contrasted nucleoli. These morphologies could be observed both in control (e) and FSHD cultures (f-h illustrate FSHD2, FSHD3 and FSHD5, respectively). Original magnification: Â 40.
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In vivo regenerating ability
Since no FSHD animal model is currently available, immunodeficient Rag2/gcÀ/À (Rag) mice were used to assess the in vivo regenerating ability of xenogenic myoblasts. Although they do not present any muscle pathology, Rag mice were chosen because they do not develop any specific immunity or antigen-dependent cell cytotoxicity. 46 FSHD myoblasts were injected twice into the tibialis anterior muscles of Rag mice preceded, in some instances, by the injection of the myotoxin notexin (Table 3) . At 1 month after MT, the expression of human proteins validated the implantation of human cells into mouse muscle fibers. 16, [47] [48] [49] Human dystrophin was observed in all cell-injected muscles, and was absent from muscles injected with a saline solution (Table 3, Figure 5 ). No significant differences were observed between muscles receiving FSHD or control myoblasts (P40.8). In the absence of notexin, the dystrophinpositive fibers were of small diameter and frequently trapped within muscle fascicles. Notexin administration did not significantly affect the number of dystrophinpositive fibers (P40.1), but these appeared more scattered within the muscle.
Discussion
The present study has been performed to evaluate the concept of autologous MT as a therapeutic tool for Production and characterization of FSHD myoblasts J-T Vilquin et al patients presenting with a hereditary muscle disorder characterized by a composed pattern of affected and unaffected muscles. This approach would avoid the immunological drawbacks met in heterologous MT clinical trials developed for generalized muscular dystrophies, and it relies on the assumption that, in regional myopathies, clinically unaffected muscles could be a source of myoblasts functionally able to participate in affected muscles regeneration. To our knowledge, this concept has not been proven yet. To establish its pertinence, it was necessary (i) to choose an appropriate pathological model; (ii) to set up and validate a specific cell culture methodology in order to produce, from unaffected muscles, a large amount of myoblasts in a delay compatible with their clinical use; and (iii) to characterize both in vitro and in vivo these cells. Among muscular dystrophies presenting with localized muscular involvement, we have selected FSHD, the third most common inherited muscular dystrophy, which is characterized by a typical regional distribution of muscle weakness, an established molecular diagnosis, and an absence of therapeutic solution. We explored proliferation and in vitro and in vivo differentiation of myoblasts prepared from unaffected vastus lateralis muscle of five FSHD patients presenting a mild phenotype and D4Z4 repeats number ranging from 6 to 10. Beyond the simple large-scale cell production, our study has been designed to evaluate the characteristics of the cells at any step of the culture, in order to standardize the comparison between these cell cultures and that of control myoblasts prepared from the same muscle of 10 healthy donors. We assumed that these controls could be considered as a baseline reference, since they have undergone a previous successful use in large-scale clinical trials.
Using a validated cell culture methodology, we were able to produce 10 9 FSHD myoblasts within 23 days.
They presented normal morphology, high and sustained viability, thus the methodologies (including enzymatic treatments and mechanical constraints) elected for cell production were considered harmless for these cells. Both FSHD and control cultures presented a high degree of purity. Myoblasts and, upon differentiation, myotubes, expressed specific muscular markers. No differences between FSHD and control cells were observed in term of in vitro differentiation. This study is the first demonstration that large-scale production of myoblasts from unaffected muscles of FSHD patients is feasible within a short delay, standardized, reproducible and fulfilling the clinical requirements. The production was even possible in a critical situation (eg FSHD2 cells). Interestingly, FSHD myoblasts obtained in our study did not present any morphological aberrations when compared to controls. This finding contrasts with a previous report on FSHD myoblasts carrying three to six D4Z4 repeats, showing a 'vacuolar-necrotic phenotype'. 50 We cannot conclude about this discrepancy because many variables could be involved as, for example, the anatomical location of muscle biopsy, the degree of muscular dystrophy and the cell culture parameters. It may also be due to differences in the genetic status of FSHD patients, since our patients had larger (six to 10) D4Z4 repeats.
Our study also underlines some differences between FSHD myoblasts prepared from unaffected muscles and myoblasts prepared from patients presenting with DMD or congenital myotonic dystrophy (CMD). In fact, the proportion of CD56-and desmin-positive FSHD myoblasts remained high throughout the production, while DMD myoblasts have been reported to display an inexorable and rapid decline during consecutive passages [11] [12] [13] 51 (personal communication), and to undergo premature senescence, although they generally keep the ability to form myotubes in vitro. FSHD myoblasts Immunodeficient Rag mice (12 weeks old) were injected with patient or control myoblasts at 1-week interval (n ¼ 2-5 muscles for each condition). The cells were used at P6 and P7, and the percentage of CD56-positive myoblasts was estimated by FACS on the day of MT. a Two protocols were followed: (1) one group received 100 ng of notexin at two sites the day before the first cell injection. (2) The other one did not receive notexin. Then, all mice received two series of myoblast injections at 1-week interval. The specific expression of human dystrophin was assessed by immunocytochemistry, and pictures of the muscle sections were taken using a digital camera for the quantification of dystrophin-positive muscle fibers per section (n ¼ 3). No such fibers could be observed upon injection of culture medium alone. Dystrophinpositive fibers were identified in the animals injected with control or FSHD myoblasts; however, there was no significant difference between the two groups.
Production and characterization of FSHD myoblasts J-T Vilquin et al also differ from CMD myoblasts, which show reduction in proliferative ability, and delays in fusion and differentiation. 52 The proliferative ability of FSHD myoblasts was also explored by the measurement of the telomere size. The length of the telomeric DNA is an indicator of cell proliferation, its measurement reflects the past divisions and is related to the remaining proliferation ability. Myoblasts from unaffected FSHD muscles displayed a normal telomere size, contrasting with myoblasts from DMD patients or elderly people, [42] [43] [44] 53 which usually present shortened telomeres and replicative defects due to a history of cumulative proliferation and muscle regeneration. As expected, these data suggest that the pathophysiological mechanism Production and characterization of FSHD myoblasts J-T Vilquin et al leading to muscle degeneration in FSHD would differ from that involved in Duchenne or congenital myotonic dystrophies, or would not progress along the same programs. This assumption is conforted by a previous demonstration that FSHD myoblasts display a normal calcium homeostasis as opposed to DMD myoblasts. 54 The reason why some muscles are specifically affected in FSHD is not understood yet, and the role played by the myoblasts in its pathophysiology remains unknown. Our data suggest that the large-scale expansion did not trigger an in vitro expression of the FSHD disease, since the myoblasts from unaffected muscles maintained a normal morphology and a high proliferative capacity. However, the characteristics of myoblasts prepared from affected muscles have not been investigated, and it would be interesting to explore the in vitro and in vivo capacities of such myoblasts prepared using our standardized cell culture methodology. The direct comparison of the growth and differentiation characteristics of myoblasts from affected and unaffected muscles could shed light on the mechanisms leading to the specificity of muscular involvement observed in FSHD. These complementary studies would allow identifying a relationship between the dystrophic status of a muscle and the biological features of its myogenic progenitors, and could provide an indication of their role in the progression of the disease. Such a relation has been proposed in other pathological situations, such as DMD, but was not established in FSHD. In this disease, the muscle-specific involvement of local myogenic programs could lead to a restricted deregulation of myogenesis in some muscle groups.
The complete preclinical validation of autologous MT would have implied the transplantation of myoblasts from unaffected muscles into some affected muscles in FSHD animal model, but none is currently available. The use of other dystrophic animal models would not have been relevant since most of these diseases are based on monogenic alterations and their pathophysiological mechanisms are unrelated to FSHD. [55] [56] [57] [58] In the present study, human FSHD myoblasts were injected into immunodeficient Rag mice, a validated mouse model for the analysis of muscle regeneration in the context of xenogenic MT. The implantation results we obtained were close to that reported previously [47] [48] [49] and confirmed that myoblasts prepared from unaffected FSHD muscles, even used at the 6th and 7th passages, take part into in vivo muscle regeneration. The overall number of dystrophin-positive fibers was inferior to that reported previously in immunocompetent models of muscular dystrophies in the context of syngenic or allogenic MT. 17, 18, 20 In these models, however, dystrophic muscles frequently undergo spontaneous cycles of degeneration/ regeneration that would increase myoblast incorporation within host tissue. In the present study, the evaluation of transplantation outcome has been performed 1 month after transplantation, a time course that is of general use in human and animal MT assays. 9, 16, 17, 20, 31, 47, 49 This model was not regarded helpful to evaluate the longterm persistence of muscle fibers harboring the human mutated genes. Indeed, a negative selection of muscle fibers expressing the mutated gene could occur with time in the healthy environment of mouse muscle fibers, and this selection would not be representative of the situation presented in FSHD.
In conclusion, the present study suggests that myoblasts prepared from unaffected muscles of FSHD patients may tolerate the large-scale expansions required for their clinical use, given the large number of cells presently needed to perform intramuscular injections. 31, 34 These myoblasts also preserve, at different passages, their ability to in vitro differentiate and to in vivo participate to muscle regeneration. The combination of our results and studies on intramuscular injection procedures raise the possibility of future clinical trials of autologous cell therapy for FSHD patients. Moreover, this standardized cell culture methodology could allow in the future the preparation and the assessment of myoblasts from patients presenting with other forms of muscular dystrophies, either in view of similar autologous MT approaches or to establish cellular models of these diseases.
Materials and methods
Patient selection
This preclinical study was approved by the French Regulatory Health Authorities and our Ethics committee (CCPPRB, Nice, France).
Eligibility for inclusion of FSHD patients was based on: (1) Historical control culture data were collected from a previous phase I clinical trial dedicated to the evaluation of MT as a therapeutic approach for postischemic heart failure. 34 In this study, 10 patients received intramyocardial transplantation of autologous myoblasts prepared according to the same validated procedure. The exclusion criteria have been described previously, 34 one of which being the absence of muscular dystrophy.
Muscle biopsy
A 1 g biopsy of the vastus lateralis muscle was performed in FSHD patients under local anesthesia, weighed, placed into a preservation medium containing antibiotics (gentamicin, 50 mg/ml, Panpharma) and sent overnight to the cell therapy laboratory.
The vastus lateralis muscle biopsies from control patients were obtained through the same procedure. The initial biopsy retrieved from these patients was larger (up to 14 g) to comply with shorter production delays required by the specific schedule of the clinical trial.
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Cell culture Set-up of culture. Cell culture procedures were agreed by the French Health Authorities (AFSSAPS) and were applied identically to FSHD and control groups. The muscle biopsies were received and processed in a dedicated clean room according to Good Manufacturing Practices. The biopsies were processed 24 h after collection (D1) for FSHD patients, and 4-6 h after collection (D0) for controls, due to a shortened transportation procedure. The muscle fragments were minced and digested using collagenase (1 h at 371C, Roche-Boehringer), then trypsin-EDTA (0.25%, 20 min at 371C, Hyclone-Perbio). The cell suspension was filtered through 100 then 40 mm cell strainers (Becton-Dickinson) and pelleted. All subsequent handlings were performed in close systems using custom-made plastic connections and bags. The cells were seeded onto a one-layer substrate (600 cm 2 , Nunc) in the proliferation medium containing: 80% of modified MCDB medium (custommade by Hyclone-Perbio), 20% Defined fetal bovine serum (DFBS, Hyclone), penicillin (100 U/ml, Sarbach) and streptomycin (10 mg/ml, Specia), 10 ng/ml human recombinant bFGF (R&D) and 1 mM dexamethasone (Merck).
Culture expansion. The cells were settled for 7 days, then harvested by trypsinization and expanded. One fraction was reserved for counting and phenotypic analysis (see below). Expansions were repeated successively, before reaching confluence (Table 1) . Up to 26 layers were required to reach the expected number of cells.
The number of divisions (n) between each passage was calculated as:
The doubling time (D) was calculated as:
where C x is the number of cells harvested at a considered passage x and C xÀz is the number of cells at a given, previous (xÀz) passage. h is the number of hours between passages x and xÀz.
Residual proliferation ability. An aliquot of cells was further subcultured to evaluate the potential maximal yield that could be achieved before the drop of CD56-positive population below the level of 50%. This limit was fixed as an indicator of the exhaustion of the myogenic potential. Briefly, 10 6 cells were plated into a 25 cm 2 flask (Falcon), and then harvested before reaching confluence. Cells were counted and a phenotypic analysis was performed. One million cells was further plated into a 25 cm 2 flask and this operation was repeated as long as cell growth was ongoing. The final theoretical yield was obtained by the multiplication of the expansion ratios observed at each passage.
Cell viability. Cell viability was evaluated by FACS (FACSCalibur, BD-Pharmingen), based on the property of exclusion of propidium iodide (0.1 mg/ml, 2 min at room temperature, Sigma) by living cells.
Microbiological controls. Microbiological controls
were performed complying with the standard protocols defined for bacteriological controls of blood-derived products prepared in clinical practice at Saint Louis Hospital (Paris, France). Samples were tested for the presence of aerobic or anaerobic pathogens at all steps of the production using the Vitale system (Merieux).
Phenotypical characterization CD56 evaluation. The cells were incubated with the phycoerythrin-coupled anti-CD56 antibody (clone NCAM 16.2, 1/5, 15 min at 41C, BD-Pharmingen). Nonspecific labeling was evaluated using the control isotype (IgG2b, BD-Pharmingen). FACS data (at least 10 4 events) were analysed using the Cell Quest software.
Desmin evaluation. The cells were first fixed and permeabilized using saponine (0.1%) in PAF (4%, 20 min at room temperature), then incubated with the anti-desmin antibody (Clone D33, 1/100, 15 min at room temperature, Dako) or the isotypic control (IgG1, 1/25, BD-Pharmingen). The cells were incubated with the secondary antibody (Goat F (ab 0 ) 2 anti-mouse H+L) coupled to FITC (1/50, 30 min at room temperature, Caltag) and analysed by FACS.
The characteristics of myoblasts (number of divisions, doubling time) were calculated as above. The true number of myoblasts (M p ) at a given passage (p) was calculated as follows:
where C p is the total number of cells at the passage p, and F p is the fraction of these cells positive for CD56 antigen.
Differentiation. Following cell harvest, 5 Â 10 5 cells were seeded into 25 cm 2 flasks and allowed to settle and proliferate for 72 h. Differentiation was induced by replacement of the proliferation medium by the differentiation medium containing the modified MCDB medium (98%), DFBS (2%) and antibiotics. Microphotographs (Olympus microscope equipped with a Photometrics Cool snap digital Camera) were performed at the onset of differentiation (D0) and 6 days later. In parallel, 2 Â 10 4 cells were seeded into 12-well plates, allowed to proliferate for 72 h. Following induction of differentiation, cells were permeabilized and fixed by cold methanol at D0, D1, D3 and D6. The expression of CD56, desmin and MyHC isoforms was assessed using anti-CD56, anti-desmin, anti-fast MyHC (clone MY32, 1/400, 1 h, Sigma) or anti-slow MyHC (clone NOQ7.5.4D, 1/1000, 1 h, Sigma) followed by a goat anti-mouse antibody (Alexa Fluor 568, 1/1000, 1 h, Molecular Probes). The presence or absence of labeled structures was evaluated qualitatively using an inverted Olympus microscope equipped for fluorescence analysis. The fusion index was calculated on four to seven microscopic fields (at least 1000 nuclei counted) using the formula:
FI ¼ððnumber of nuclei within myotube structuresÞ =ðtotal number of nuclei in the fieldÞÞÂ100
Evaluation of telomere size. DNA samples were extracted from cell pellets, digested by HinfI (Biolabs) for 2 h at 371C to generate terminal restriction fragments Production and characterization of FSHD myoblasts J-T Vilquin et al (TRFs) containing the telomeric region with several kb pairs of the (TTAGGG) repeat sequence and a subtelomeric region of non-TTAGGG DNA. 42 Digested genomic DNA (3 mg), as well as molecular markers ( 32 P ladder 1 kb and HMW, Life Technologies) were resolved by electrophoresis for 1400 V h in 0.7% agarose gel. The TRFs were detected by hybridization to a 32 P-(TTAGGG) 4 probe as described. 42 The signals on hybridized gels were quantified using a phosphorimager (Biorad) and analyzed by a computer-assisted system 43, 53 (n ¼ 3 for each determination). The hybridized signals were normalized to have equalized signal intensities. The high purity of myoblasts in the cultures allows attributing the telomere size to this population.
In vivo implantation. To evaluate their ability to take part in muscle formation in vivo, the myoblasts were injected into the tibialis anterior muscles of immunodeficient Rag mice (kindly provided by Dr James Di Santo). 46 The cell implantation model had been validated previously. 47 Aliquots of cells were thawed and grown in one single plate (600 cm 2 , Nunc) in proliferation medium. The myoblasts were then used at P6 and P7. On the day of injection, they were harvested, counted and an aliquot was reserved for the quantification of CD56-positive cells by FACS. Cells were finally suspended in DMEM (Gibco-BRL) containing 0.5% BSA (Sigma) and kept on ice until the injection. Animals were anesthetized using ketamine (30 mg/kg) and xylazine (15 mg/kg). The tibialis anterior muscle was exposed by a small skin incision. Two protocols were followed ( Table 3 ). The mice received two series of cell injections at one week interval. 2 to 5 Â 10 6 cells were injected at 8 to 10 sites in a volume of 20 ml using a glass capillary.
The mice were killed 4 weeks after the last series of cell injections, which is a delay compatible with complete mouse muscle regeneration and the expression of donor markers. 16, [47] [48] [49] The muscles were snap frozen in nitrogen-cooled isopentan and serially sectioned (8 mm) using a cryostat. The participation of human cells in muscle formation was detected by the specific expression of human dystrophin beneath the basement membrane of muscle fibers. The Mouse on Mouse kit (Vector) was used. Sections were incubated with the anti-dystrophin antibody (NCL-Dys3, 1/20, 30 min at room temperature, Novocastra), and then with a goat anti-mouse IgG (H+L) (Alexa Fluor 568, 1/1000, 30 min at room temperature, Molecular Probes). Slides were mounted under Mowiol (Calbiochem) and observed using a Zeiss fluorescence microscope. Pictures were performed using the Photometric digital camera and used for the quantification of the number of dystrophin-positive fibers. Statistical analysis was performed using the paired t-test.
